Reassessing oral lead-in for injectable long-acting HIV therapy
- PMID: 34656209
- DOI: 10.1016/S2352-3018(21)00269-1
Reassessing oral lead-in for injectable long-acting HIV therapy
Conflict of interest statement
JML reports consulting honoraria from ViiV Healthcare, Gilead Sciences and Janssen-Cila; and research grants from Gilead Sciences and ViiV Healthcare. PES has served on advisory boards and received grants and personal fees from Gilead, ViiV Healthcare, Janssen, and Merck.
Comment on
-
Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study.Lancet HIV. 2021 Nov;8(11):e668-e678. doi: 10.1016/S2352-3018(21)00184-3. Epub 2021 Oct 14. Lancet HIV. 2021. PMID: 34656207 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
